CPAH stock: buy or sell?
February 21st, 2020
CounterPath Corporation designs, develops, markets, and sells software applications and related services in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
Should I buy CPAH stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with CounterPath stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is CounterPath stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for CPAH stock for the last 30 days.
CPAH stock analysis
After boosting an outstanding 10.48% yesterday, CounterPath closed today at $2.42 and eased a fateful -2.42%.
After boosting an outstanding 10.48% yesterday, CounterPath closed today at $2.42 and eased a fateful -2.42%. Since yesterday when SMA100d and SMA200d crossed up, CPAH price gained $0.20 per share (9.01%). Since price and SMA200d lines crossed up on Jan 10th, CPAH climbed $1.43 (144.44%).
After boosting an amazing 8.61% in a week last week, CounterPath closed this week at $2.42 and slightly fell an unpleasant -0.82%. Late January CPAH plunged a spooky -26.32% in just one week.
Having descending tops is not good news for investors in CPAH. Although it's only a warning signal, traders should be on alert during next weeks to identify possible new risks. Sliding under its previous bottom at would confirm the downtrend path. Since SMA20d and SMA40w crossed up early February, CPAH price climbed $0.29 per share (13.62%). Since price and SMA40w lines crossed up early January, CPAH climbed $1.44 (146.94%).
CPAH stock price history
CPAH IPO was on April 7th, 2004 at $0.90 per share1. Since then, CPAH stock surged a 168.90%, with an average of 11.30% per year. If you had invested $1,000 in CPAH stock in 2004, it would worth $1,689.00 today.
1: Adjusted price after possible price splits or reverse-splits.
CPAH stock historical price chart
CPAH stock reached 52-week highs on Jan/13 at $6.00, and all-time highs 2004-09-20 with a price of 147.
CPAH stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we have not detected any price forecast for CounterPath stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince March, when CounterPath presented its last earnings report, it . As soon as we get its actual EPS from the earnings report, we will extend this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, CounterPath annual sales remained stable a neutral 0.01% to $12.38 M USD from $12.38 marked in 2018. When comparing 2018 vs 2018, aligned with this, profit margin (that is, the net income divided by revenues) stayed constant a 0.00% to -26.01%. To have an up to date view of the financial situation of CounterPath, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2019-Q1 that can be compared to 2018 fiscal year results. Annual CounterPath TTM sales up to January 2019 were $10.69 and earnings were $-5.58 M dollars. If we compare this TTM figures with the last reported annuality, we can review CounterPath business evolution since April 2018: Annual revenues up to January, compared to lastest yearly report, collapsed a bloodcurdling -13.65%. Likewise, profit margin (net income/revenues) plunged at -26.01%.
|2014||$12 M||-||$-5.91 M-50.6%||-|
|2014||$12 M||0.00%||$-5.91 M-50.6%||0.00%|
|2015||$12 M||2.74%||$-4.44 M-37.0%||-24.87%|
|2015||$12 M||0.03%||$-4.44 M-37.0%||0.04%|
|2016||$11 M||-7.69%||$-2.69 M-24.3%||-39.44%|
|2016||$11 M||0.01%||$-2.69 M-24.3%||0.06%|
|2017||$11 M||-3.53%||$-2.46 M-23.0%||-8.60%|
|2017||$11 M||-0.04%||$-2.46 M-23.0%||-0.06%|
|2018||$12 M||15.86%||$-3.22 M-26.0%||30.97%|
|2018||$12 M||0.01%||$-3.22 M-26.0%||0.02%|
|TTM||$11 M||-13.65%||$-5.58 M-52.2%||73.34%|
Quarterly financial resultsCounterPath posted $2.59 M in sales for 2019-Q1, a 6.00% up compared to previous quarter. Reported quarter earnings marked $-1.06 M with a profit margin of -40.94%. Profit margin skyrocketed a 43.60% compared to previous quarter when profit margin was -84.54%. When comparing turnover to same quarter last year, CounterPath sales marked a spooky slide and plunged a -16.09%.
|2017-Q2||$2 M||-||$-0.85 M-36.1%||-|
|2017-Q3||$3 M||32.34%||$-1.15 M-37.0%||35.54%|
|2017-Q4||$3 M||9.66%||$0.16 M4.7%||-113.81%|
|2018-Q1||$3 M||-9.58%||$-0.78 M-25.2%||-590.04%|
|2018-Q2||$3 M||-10.03%||$-1.45 M-52.2%||86.12%|
|2018-Q3||$3 M||4.09%||$-1.01 M-35.0%||-30.21%|
|2018-Q4||$2 M||-15.46%||$-2.06 M-84.5%||104.14%|
|2019-Q1||$3 M||6.00%||$-1.06 M-40.9%||-48.67%|
CounterPath ownershipWhen you are planning to invest in a company, it's always worth to check its ownership structure.
CounterPath shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 51.51% of all shares.
In case of CounterPath stock, 1.66% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CPAH stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$14.4 M|
|Total shares||6.0 M|
|Float shares||3.0 M|
|- Institutional holdings (%)||1.7%|
|- Insider holdings (%)||51.5%|
|Shares in short selling||0.0%|
|Friday, February 21st, 2020|
|Day range||$2.34 - $2.45|
|Average true range||$0.29|
|50d mov avg||$1.80|
|100d mov avg||$1.46|
|200d mov avg||$1.45|
CounterPath performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare CounterPath performance to :